CD274 and hepatocellular carcinoma: Although great breakthroughs have been made in the evolution of surgical removal, chemotherapy, radiofrequency ablation, transarterial chemoembolization, tyrosine kinase inhibitors or immune checkpoint inhibitors such as anti-programmed cell death (/ligand) 1 (PD1/PDL1) immunotherapy, the survival outcomes of advanced HCC patients are still frustrating [2–4].